Market Overview

Leerink Upgrades Mylan On Barrage Of Catalysts, Diversified Platforms

Share:
Leerink Upgrades Mylan On Barrage Of Catalysts, Diversified Platforms

Mylan NV (NASDAQ: MYL)’s had a rough three years, but one analyst left the pharma company's investor day with fresh optimism.

The Rating

Leerink analyst Ami Fadia upgraded Mylan from Market Perform to Outperform and maintained a $52 price target.

The Thesis

By Leerink’s assessment, Mylan is positioned to strengthen its balance sheet and deliver 4-percent top-line and low-double digit bottom-line compound annual growth through 2023.

“Mylan’s biosimilars/complex products pipeline is shaping up to be one of the strongest in the industry,” Fadia said in a Thursday note.

The company has near-term, upside-driving catalysts in upcoming approvals or launches of biosimilars of Neulasta, Humira and Herceptin; generics of Advair and Restasis; and new products revefenacin and glargine, according to Leerink. 

“We are incrementally more positive on the potential for Advair’s approval this year,” Fadia said, anticipating a fast ramp and few near-term competitors. “[...] Even if it were to be delayed by a few months, we continue to see generic Advair as a meaningful contributor for 2019.”

The candidate is forecast to contribute 35 cents to 2019 earnings per share and build on a well-diversified portfolio. With over-the-counter and branded drugs accounting for 40 percent of revenue, 60 percent of sales recorded outside the U.S. and no single product representing more than 4 percent of sales, Mylan has its bases covered, Fadia said. 

“Mylan’s diversified business model remains under-appreciated, in our view,” the analyst said, noting that it needs no gap-filling acquisitions.

Price Action

Shares popped as much as 2.1 percent on the upgrade. At the time of publication, Mylan was up 1.66 percent at $41.06. 

Related Links:

Teva Vs Mylan: Wells Fargo Weighs In

Mylan Inks Deal With Mapi Pharma For Multiple Sclerosis Drug

Latest Ratings for MYL

DateFirmActionFromTo
Nov 2019DowngradesOverweightEqual-Weight
Sep 2019MaintainsBuy
Jul 2019ReiteratesOverweight

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Advair Ami FadiaAnalyst Color Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (MYL)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ARAVH.C. WainwrightReiterates31.0
QCOMCascendReiterates110.0
KMPHH.C. WainwrightReiterates2.5
HASusquehannaInitiates Coverage On27.0
BFRABenchmarkMaintains18.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Bed Bath & Beyond Falls 20% Amid Weak 2018 Outlook

Mid-Day Market Update: Dow Rises Over 300 Points; Novavax Shares Plunge